AKR7L: A Potential Drug Target and Biomarker for Alzheimer's disease

Target Name: AKR7L

NCBI ID: G246181

AKR7L

AKR7L: A Potential Drug Target and Biomarker for Alzheimer's disease

introduction

Alzheimer's disease is a typical degenerative disease of the nervous system, which mainly manifests as cognitive function decline, memory loss, and gradually increasing severity of neuron death. Currently, the treatment of Alzheimer's disease remains a challenging problem, and although some progress has been made, there is still no effective way to completely cure the disease. Therefore, finding new therapeutic targets and biomarkers has important clinical significance.

AKR7L: a potential drug target

AKR7L (alpha-ketoglutarate dehydrogenase 7-like) is a protein located in the mitochondrial matrix and is a member of the mitochondrial complex family. Under normal circumstances, AKR7L is mainly involved in the aerobic oxidation process of glucose on the inner mitochondrial membrane, helping to maintain the stability of cellular energy metabolism. However, in Alzheimer's disease patients, the activity of AKR7L is altered, resulting in reduced aerobic oxidation of glucose at the inner mitochondrial membrane.

In recent years, researchers have discovered abnormal expression of AKR7L in Alzheimer's disease patients, indicating that AKR7L may play an important role in Alzheimer's disease. In addition, some studies have also shown that the activity of AKR7L is regulated by some biological molecules, such as phosphatidylinositol and triglycerides. These findings raise interest in AKR7L as a therapeutic target for Alzheimer's disease.

AKR7L: a potential biomarker

The abnormal expression of AKR7L in Alzheimer's disease and its role in biomolecule regulation make it a potential biomarker. By detecting AKR7L expression levels in patients, the progression of the disease and the effectiveness of treatment can be assessed. In addition, the expression level of AKR7L can also be used as a biological target for the treatment of Alzheimer's disease, providing guidance for the clinical development of new treatments.

AKR7L: a potential drug target

Despite AKR7L's important role in Alzheimer's disease, there are currently no specific drugs targeting it. Therefore, its research and development as a drug target has important clinical significance. Drug intervention targeting AKR7L can reduce the aerobic oxidation process of glucose on the inner mitochondrial membrane, thereby slowing the progression of Alzheimer's disease.

In addition, the activity of AKR7L is regulated by some biomolecules, which may become targets for drug intervention. For example, phosphatidylinositol and triacylglycerol can modulate the activity of AKR7L, therefore, by targeting these molecules, the function of AKR7L can be affected. These findings provide an important theoretical basis for pharmacological intervention of AKR7L.

in conclusion

AKR7L is a potential molecule as a therapeutic target for Alzheimer's disease. By studying the biological functions and pharmacological properties of AKR7L, new treatment methods and biological targets can be discovered, bringing revolutionary changes to the treatment of Alzheimer's disease. Although the current pharmacological intervention of AKR7L is still in the exploratory stage, it deserves further research and development as a potential drug target.

Protein Name: Aldo-keto Reductase Family 7 Like (gene/pseudogene)

Functions: Can reduce the dialdehyde protein-binding form of aflatoxin B1 (AFB1) to the non-binding AFB1 dialcohol. May be involved in protection of liver against the toxic and carcinogenic effects of AFB1, a potent hepatocarcinogen (By similarity)

The "AKR7L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AKR7L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets